Envestnet Asset Management Inc. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 68.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,025 shares of the company’s stock after purchasing an additional 57,121 shares during the period. Envestnet Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,061,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in TEVA. Quantbot Technologies LP acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $110,000. Atlas Capital Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 18.6% in the 1st quarter. Atlas Capital Advisors LLC now owns 12,677 shares of the company’s stock valued at $119,000 after purchasing an additional 1,987 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 15.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 12,690 shares of the company’s stock valued at $119,000 after purchasing an additional 1,713 shares during the period. Stephens Inc. AR purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter worth $126,000. Finally, Scotia Capital Inc. increased its holdings in Teva Pharmaceutical Industries by 19.6% in the 1st quarter. Scotia Capital Inc. now owns 13,631 shares of the company’s stock worth $128,000 after acquiring an additional 2,234 shares in the last quarter. 46.22% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Trading Down 1.9 %
Shares of TEVA opened at $8.80 on Thursday. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. Teva Pharmaceutical Industries Limited has a 12-month low of $6.78 and a 12-month high of $11.34. The firm has a 50-day moving average price of $8.54 and a 200 day moving average price of $8.63. The firm has a market capitalization of $9.77 billion, a P/E ratio of -7.59 and a beta of 1.27.
Analyst Upgrades and Downgrades
Several brokerages recently commented on TEVA. JPMorgan Chase & Co. lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $11.00 to $10.00 in a report on Monday, November 14th. The Goldman Sachs Group boosted their price target on shares of Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Tuesday, August 2nd. StockNews.com began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 12th. They issued a “buy” rating for the company. UBS Group lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a report on Friday, November 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Friday, October 21st. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.44.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.